Category: 4. Acute Coronary Syndromes: Therapy Background: Ticagrelor is superior to clopidogrel for prevention of the combined rate of cardiovascular (CV) death, myocardial infarction (MI) and stroke in acute coronary syndromes (ACS).(1) Patients with two loss-of-function (LOF) alleles at CYP2C19, the main genetic factor affecting clopidogrel PK/PD, are classified as poor metabolizers (PM) of clopidogrel. We used the PLATO genetic sub-study to assess the impact of PM on the overall PLATO result.
